Straits Times Index
3,145.81 -5.75 (-0.18%) Nikkei
27,116.11 -195.19 (-0.71%) Hang Seng
17,740.05 -272.10 (-1.51%) FTSE 100
6,991.09 -6.18 (-0.09%) BTC-USD
19,471.02 -550.51 (-2.75%) CMC Crypto 200
444.26 -10.77 (-2.37%)
Lonza Group AG (LZAGY)
| Previous close | 50.93 |
| Open | 50.38 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 49.84 - 50.58 |
| 52-week range | 43.85 - 85.18 |
| Volume | |
| Avg. volume | 133,760 |
| Market cap | 37.638B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 39.94 |
| EPS (TTM) | 1.25 |
| Earnings date | N/A |
| Forward dividend & yield | 0.30 (0.59%) |
| Ex-dividend date | 09 May 2022 |
| 1y target est | 89.00 |
- Reuters
Lonza's first-half core EBITDA gains 16.5%
(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.
- Reuters
Lonza's full-year core EBITDA up 20.7% on vaccine demand
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
- Motley Fool
Should You Have Lonza Stock on Your Watchlist?
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
